심방세동에서의 항응고요법
Anticoagulation in Atrial Fibrillation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Atrial fibrillation (AF) is the most commonly occurring arrhythmia. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with non-valvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, they possess numerous limitations that curtail their use, or make their use challenging for clinicians and patients. A new generation of anticoagulants are being investigated in clinical trials in patients with AF. One or more of these agents have the potential to either replace or act as alternatives to VKA therapy in AF. This review summarizes the recent accumulated evidence on anticoagulation to prevent the thromboembolism in patients with non-valvular AF. (Korean J Med 2011;81:434-443)
Abstract
Atrial fibrillation (AF) is the most commonly occurring arrhythmia. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with non-valvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, they possess numerous limitations that curtail their use, or make their use challenging for clinicians and patients. A new generation of anticoagulants are being investigated in clinical trials in patients with AF. One or more of these agents have the potential to either replace or act as alternatives to VKA therapy in AF. This review summarizes the recent accumulated evidence on anticoagulation to prevent the thromboembolism in patients with non-valvular AF. (Korean J Med 2011;81:434-443)
참고문헌 (21)
- Wolf PA, "Atrial fibrillation as an independent risk factor for stroke: the Framingham Study", Stroke, 22, pp.983~988 (1991)
- Hart RG, "Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis", Ann Intern Med, 131, pp.492~501 (1999)
- Camm AJ, "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Europace, 32, pp.1172~ (2011)
- Wann LS, "2011 ACCF", AHA, American Heart Association Task Force on Practice Guidelines, pp.Circulation, 2011[DOI]
- Wann LS, "2011 ACCF", AHA, American Heart Association Task Force on practice guidelines, pp.J Am Coll Cardiol, 2011[DOI]
- Petersen P, "Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study", Lancet, 1, pp.175~179 (1989)
- "Stroke Prevention in Atrial Fibrillation Study: final results", Circulation, 84, pp.527~539 (1991)
- The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, "The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators", N Engl J Med, 323, pp.1505~1511 (1990)
- Ezekowitz MD, "Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators", N Engl J Med, 327, pp.1406~1412 (1992)
- Connolly SJ, "Canadian Atrial Fibrillation Anticoagulation (CAFA) Study", J Am Coll Cardiol, 18, pp.349~355 (1991)
- "Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group", Lancet, 342, pp.1255~1262 (1993)
- Connolly SJ, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation", N Engl J Med, 360, pp.2066~2078 (2009)
- Connolly S, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial", Lancet, 367, pp.1903~1912 (2006)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Pisters R, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
- Wyse DG, "A comparison of rate control and rhythm control in patients with atrial fibrillation", N Engl J Med, 347, pp.1825~1833 (2002)
- Van Gelder IC, "A comparison of rate control and rhythm controlin patients with recurrent persistent atrial fibrillation", N Engl J Med, 347, pp.1834~1840 (2002)
- Holmes DR, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial", Lancet, 374, pp.534~542 (2009)